Michael S Leapman1,2, Kimberly Stone3, Roxanne Wadia1,2, Lesley S Park4, Cynthia L Gibert5,6, Matthew B Goetz7,8, Roger Bedimo9, Maria Rodriguez-Barradas10, Fatma Shebl1, Amy C Justice2, Sheldon T Brown4,11, Kristina Crothers12, Keith M Sigel3. 1. Yale University, New Haven, Connecticut. 2. VA Connecticut Healthcare System, West Haven, Connecticut. 3. Icahn School of Medicine at Mt Sinai, New York, New York. 4. Stanford University, Stanford, California. 5. George Washington University, Washington, District of Columbia. 6. Washington District of Columbia VA Medical Center, Washington, District of Columbia. 7. University of California Los Angeles, Los Angeles, California. 8. VA Greater Los Angeles Healthcare System, Los Angeles, California. 9. University of Texas Southwestern, Dallas, Texas. 10. Baylor College of Medicine, Houston, Texas. 11. James J. Peters VA Medical Center, Bronx, New York. 12. University of Washington, Seattle, Washington.
Abstract
PURPOSE: The risk of prostate cancer among persons living with human immunodeficiency virus (PWH) is not well understood and may be obscured by different opportunities for detection. MATERIALS AND METHODS: We identified 123,472 (37,819 PWH and 85,653 comparators) men enrolled in the Veterans Aging Cohort Study, a prospective national cohort of PWH and demographically matched, uninfected comparators in 2000-2015. We calculated rates of prostate specific antigen (PSA) testing by human immunodeficiency virus (HIV) status and fit multivariable Poisson models comparing the rates of PSA testing, prostate biopsy, and cancer incidence. RESULTS: The mean age at enrollment was 52 years. Rates of PSA testing were lower in PWH versus uninfected comparators (0.58 versus 0.63 tests per person-year). Adjusted rates of PSA screening and prostate biopsy were lower among PWH (incidence rate ratio [IRR] 0.87, 95% CI 0.75-0.84 and IRR 0.79 95% CI 0.74-0.83, respectively). The crude IRR for prostate cancer was lower in PWH versus controls (IRR 0.90, 95% CI 0.83-0.97). However, in a multivariable model adjusting for PSA testing, cancer incidence was similar by HIV status (IRR=0.93, 95% CI 0.86-1.01, p=0.08). Among patients who received a prostate biopsy, incidence of prostate cancer did not differ significantly by HIV status (IRR 1.06, 95% CI 0.98-1.15, p=0.15). Among incident cancers, there were significant differences in the distributions of Gleason grade (p=0.05), but not cancer stage (p=0.14) by HIV status. CONCLUSIONS: When accounting for less PSA testing among PWH, the incidence of prostate cancer was similar by HIV status. These findings suggest that less screening contributed to lower observed incidence of prostate cancer in PWH.
PURPOSE: The risk of prostate cancer among persons living with human immunodeficiency virus (PWH) is not well understood and may be obscured by different opportunities for detection. MATERIALS AND METHODS: We identified 123,472 (37,819 PWH and 85,653 comparators) men enrolled in the Veterans Aging Cohort Study, a prospective national cohort of PWH and demographically matched, uninfected comparators in 2000-2015. We calculated rates of prostate specific antigen (PSA) testing by human immunodeficiency virus (HIV) status and fit multivariable Poisson models comparing the rates of PSA testing, prostate biopsy, and cancer incidence. RESULTS: The mean age at enrollment was 52 years. Rates of PSA testing were lower in PWH versus uninfected comparators (0.58 versus 0.63 tests per person-year). Adjusted rates of PSA screening and prostate biopsy were lower among PWH (incidence rate ratio [IRR] 0.87, 95% CI 0.75-0.84 and IRR 0.79 95% CI 0.74-0.83, respectively). The crude IRR for prostate cancer was lower in PWH versus controls (IRR 0.90, 95% CI 0.83-0.97). However, in a multivariable model adjusting for PSA testing, cancer incidence was similar by HIV status (IRR=0.93, 95% CI 0.86-1.01, p=0.08). Among patients who received a prostate biopsy, incidence of prostate cancer did not differ significantly by HIV status (IRR 1.06, 95% CI 0.98-1.15, p=0.15). Among incident cancers, there were significant differences in the distributions of Gleason grade (p=0.05), but not cancer stage (p=0.14) by HIV status. CONCLUSIONS: When accounting for less PSA testing among PWH, the incidence of prostate cancer was similar by HIV status. These findings suggest that less screening contributed to lower observed incidence of prostate cancer in PWH.
Authors: Lesley S Park; Janet P Tate; Maria C Rodriguez-Barradas; David Rimland; Matthew Bidwell Goetz; Cynthia Gibert; Sheldon T Brown; Michael J Kelley; Amy C Justice; Robert Dubrow Journal: J AIDS Clin Res Date: 2014-07
Authors: Meredith S Shiels; Ruth M Pfeiffer; Mitchell H Gail; H Irene Hall; Jianmin Li; Anil K Chaturvedi; Kishor Bhatia; Thomas S Uldrick; Robert Yarchoan; James J Goedert; Eric A Engels Journal: J Natl Cancer Inst Date: 2011-04-11 Impact factor: 13.506
Authors: Shawn L Fultz; Melissa Skanderson; Larry A Mole; Neel Gandhi; Kendall Bryant; Stephen Crystal; Amy C Justice Journal: Med Care Date: 2006-08 Impact factor: 2.983
Authors: Lesley S Park; Janet P Tate; Keith Sigel; Sheldon T Brown; Kristina Crothers; Cynthia Gibert; Matthew Bidwell Goetz; David Rimland; Maria C Rodriguez-Barradas; Roger J Bedimo; Amy C Justice; Robert Dubrow Journal: Ann Intern Med Date: 2018-06-12 Impact factor: 25.391
Authors: Ionut Bebu; Janet Tate; David Rimland; Octavio Mesner; Grace E Macalino; Anuradha Ganesan; Jason F Okulicz; Mary Bavaro; Amy C Weintrob; Amy C Justice; Brian K Agan Journal: J Acquir Immune Defic Syndr Date: 2014-02-01 Impact factor: 3.731
Authors: Amy C Justice; Sharada P Modur; Janet P Tate; Keri N Althoff; Lisa P Jacobson; Kelly A Gebo; Mari M Kitahata; Michael A Horberg; John T Brooks; Kate Buchacz; Sean B Rourke; Anita Rachlis; Sonia Napravnik; Joseph Eron; James H Willig; Richard Moore; Gregory D Kirk; Ronald Bosch; Benigno Rodriguez; Robert S Hogg; Jennifer Thorne; James J Goedert; Marina Klein; John Gill; Steven Deeks; Timothy R Sterling; Kathryn Anastos; Stephen J Gange Journal: J Acquir Immune Defic Syndr Date: 2013-02-01 Impact factor: 3.731
Authors: Keri N Althoff; Kathleen A McGinnis; Christina M Wyatt; Matthew S Freiberg; Cynthia Gilbert; Krisann K Oursler; David Rimland; Maria C Rodriguez-Barradas; Robert Dubrow; Lesley S Park; Melissa Skanderson; Meredith S Shiels; Stephen J Gange; Kelly A Gebo; Amy C Justice Journal: Clin Infect Dis Date: 2014-10-30 Impact factor: 9.079
Authors: Leah Shepherd; Alvaro Humberto Borges; Lene Ravn; Richard Harvey; Viard Jean-Paul; Mark Bower; Andrew Grulich; Michael Silverberg; Stephane De Wit; Ole Kirk; Jens Lundgren; Amanda Mocroft Journal: J Int AIDS Soc Date: 2014-11-02 Impact factor: 5.396